BioLineRX (BLRX) announced the filing of regulatory submissions required to commence a Phase 2a trial assessing BL-8040, in combination with Merck's (MRK) KEYTRUDA (pembrolizumab), for the treatment of pancreatic cancer. The study, called COMBAT, is expected to commence in Q3. The study is designed to evaluate the clinical response, safety and tolerability of the combination as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity in patients with metastatic pancreatic adenocarcinoma.